You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade

Authors

  • Tatiana V Kudling Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • James Clubb Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics Ltd., Helsinki, Finland PubMed articlesGoogle scholar articles
  • Santeri A Pakola Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Dafne Alves Quixabeira Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics Ltd., Helsinki, Finland PubMed articlesGoogle scholar articles
  • Iris Lähdeniemi Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Camilla Heiniö Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Victor Arias Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Susanna AM Grönberg-Vähä-Koskela Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Riikka Havunen Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics Ltd., Helsinki, Finland PubMed articlesGoogle scholar articles
  • Victor Cervera-Carrascon Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics Ltd., Helsinki, Finland PubMed articlesGoogle scholar articles
  • Joao Manuel Santos Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics Ltd., Helsinki, Finland PubMed articlesGoogle scholar articles
  • Eva Sutinen iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Jari Räsänen General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Kristian Borenius iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Mikko Mäyränpää Pathology, University of Helsinki and Helsinki University Hospital (HUSLAB), Helsinki, Finland PubMed articlesGoogle scholar articles
  • Eero Altonen Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Suvi Sorsa Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics Ltd., Helsinki, Finland PubMed articlesGoogle scholar articles
  • Otto Hemminki Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Anna Kanerva Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Emmy W Verschuren Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Ilkka Ilonen iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Akseli Hemminki Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics Ltd., Helsinki, Finland Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles

Citation

Kudling TV, Clubb J, Pakola SA, et al
814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0814
Online issue publication 
November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.